Last reviewed · How we verify
Placebo to V503
V503 is a therapeutic vaccine candidate designed to stimulate immune responses against human papillomavirus (HPV) types associated with cervical and other cancers.
V503 is a therapeutic vaccine candidate designed to stimulate immune responses against human papillomavirus (HPV) types associated with cervical and other cancers. Used for HPV-related cervical intraepithelial neoplasia (CIN), HPV-related cancers.
At a glance
| Generic name | Placebo to V503 |
|---|---|
| Sponsor | Merck Sharp & Dohme LLC |
| Drug class | Therapeutic vaccine |
| Target | Human papillomavirus (HPV) antigens |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
V503 is an investigational HPV therapeutic vaccine that aims to generate cellular and humoral immune responses targeting HPV antigens. Unlike prophylactic HPV vaccines, V503 is intended for therapeutic use in patients with existing HPV-related disease, potentially helping the immune system recognize and eliminate HPV-infected cells.
Approved indications
- HPV-related cervical intraepithelial neoplasia (CIN)
- HPV-related cancers
Common side effects
- Injection site reactions
- Fever
- Fatigue
Key clinical trials
- Efficacy, Immunogenicity, and Safety Study of the 9vHPV Vaccine in Japanese Males (V503-064) (PHASE3)
- Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049) (PHASE3)
- Efficacy, Immunogenicity, and Safety of V503 in Chinese Males (V503-052) (PHASE3)
- A Study of V503, a 9-valent Human Papillomavirus (9vHPV) Vaccine in Females 12-26 Years of Age Who Have Previously Received GARDASIL™ (V503-006) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo to V503 CI brief — competitive landscape report
- Placebo to V503 updates RSS · CI watch RSS
- Merck Sharp & Dohme LLC portfolio CI